Nephrotoxicity as a Complication of Antiretroviral Therapy

Advances in Chronic Kidney Disease

Volumn 13, Issue 3, 2006, Pages 314-319

  Valle, Ramsis ^a   Haragsim, Lukas ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Antiretrovirals; HAART; HIV; Nephrotoxicity; Opportunistic infections

Indexed keywords

ACICLOVIR; ADEFOVIR; AMPHOTERICIN B; ANTIRETROVIRUS AGENT; CIDOFOVIR; COTRIMOXAZOLE; DEOXYCHOLIC ACID; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; FOSCARNET; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PENTAMIDINE; PROBENECID; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE KIDNEY FAILURE; AMINOACIDEMIA; ARTICLE; BACTERIAL PNEUMONIA; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; CRYSTALLURIA; CYTOMEGALOVIRUS INFECTION; DIALYSIS; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DYSURIA; FANCONI RENOTUBULAR SYNDROME; FIBROSING ALVEOLITIS; FLANK PAIN; GLOMERULOSCLEROSIS; GLUCOSURIA; HEMATURIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED NEPHROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERKALEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY PAPILLA NECROSIS; KIDNEY TUBULE ACIDOSIS; KIDNEY TUBULE DISORDER; LACTIC ACIDOSIS; LEUKOCYTURIA; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MITOCHONDRIAL TOXICITY; MYCOSIS; NAUSEA; NEPHROLITHIASIS; NEPHROTIC SYNDROME; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RETINITIS; URINARY TRACT OBSTRUCTION; VOMITING;

ANTI-RETROVIRAL AGENTS; HIV; HIV INFECTIONS; HUMANS; KIDNEY DISEASES; PROGNOSIS;

EID: 33745343820     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2006.04.011     Document Type: Article

References (34)

1. Seguro A.C., De Araujo M., and Seguro F.S. Effects of hypokalemia and hypomagnesemia on Zidovudine and didanosine nephrotoxicity in rats. Clin Nephrol 59 (2003) 267-272
2. Knupp C.A. Disposition of didanosine in HIV seropositive patients with normal renal function and chronic kidney disease. Clin Pharmacol 60 (1996) 535-542
3. Tanji N., and Tanji K. Adefovir nephrotoxicity. Possible role of mitochondrial DNA depletion. Hum Pathol 32 (2001) 734-740
4. Verhelst D., Monge M., Meynard J.L., et al. Fanconi syndrome and renal failure induced by tenofovir. A first case report. Am J Kidney Dis 40 (2002) 1331-1333
5. Gallant J. Modest decline in renal function associated with tenofovir compared to NRTI treatment (2005) 12th Conference on Retroviruses and Opportunistic Infections, Boston, February 22-25
6. Day S, Date HL, Hankins M, et al: Hypophosphatemia in Patients Taking Tenofovir. Brighton, UK, Sussex University Hospital NHS Trust
7. Creput C., Gonzalez G., Hill G., et al. Renal lesions in HIV positive patient treated with tenofovir. AIDS 17 (2003) 935-937
8. Murphy M.D., O'Hearn M., and Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infect Dis 36 (2003) 1082-1085
9. Jones R., Stebbing J., and Nelson M. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active retroviral therapy regimens is not observed more frequently. A cohort and case control study. J Acquir Immune Defic Syndr 37 (2004) 1489-1495
10. Padilla S., Gutierrez F., and Masia M. Low frequency of renal function impairment during one year of therapy with tenofovir containing regimens in the real world. A case control study. AIDS Patient Care STDS 19 (2005) 421-424
11. Dieleman J.P., and Van der Feltz M. Papillary necrosis associated with HIV protease inhibitor indinavir. Infection 29 (2001) 232-233
12. Kopp J.B., Miller K.D., Mican J.A.M., et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 127 (1997) 199-125
13. Dieleman J.P., Struckenboom M.C., Jambroes M., et al. Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate. Arch Intern Med 162 (2002) 1493-1501
14. Malavaud B., Dinh B., Bonnet E., et al. Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection. Antivir Ther 5 (2000) 3-5
15. Engeler D.S., and John H. Nelfinavir urinary stones. J Urol 167 (2002) 1384-1385
16. Bochet M.V., Jacquiaud C., Valantin M.A., et al. Ritonavir induced acute renal failure in HIV infected patients. Am J Med 105 (1998) 457
17. Daugas E., Rougier J.P., and Hill G. HAART related nephropathies in HIV infected patients. Kidney Int 68 (2005) 409
18. Meier P., Dautheville-Guibal S., Ronco P.M., et al. Cidofovir-induced end-stage renal failure. Nephrol Dial Transplant 17 (2002) 148-149
19. Vittecoq D., Dumitrescu L., and Beaufils H. Fanconi syndrome associated with cidofovir therapy. (letter). Antimicrob Agents Chemother 41 (1997) 1846
20. Lachaal M., and Venuto R.C. Nephrotoxicity and hyperkalemia in patients with AIDS treated with pentamidine. Am J Med 87 (1989) 260-263
21. Shah G.M., Alvarado P., and Kirschenbaum M.A. Symptomatic hypocalcemia and hypomagnesemia with renal magnesium wasting associated with pentamidine therapy in a patient with AIDS. Am J Med 89 (1990) 380-382
22. Antoniskis D., and Larsen R.A. Acute, rapidly progressive renal failure with simultaneous use of amphotericin B and pentamidine. Antimicrob Agents Chemother 34 (1990) 470-472
23. Conte J.E., and Conte Jr. J.E. Pharmacokinetics of intravenous pentamidine in patients with normal renal function or receiving hemodialysis. J Infect Dis 163 (1991) 169-175
24. Harbarth S., and Pestotnik S.L. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 111 (2001) 528-534
25. Bates D.W., Su L., and Yu D.T. Correlates of acute renal failure in patients receiving parenteral amphoterecin B. Kidney Int 60 (2001) 1452-1459
26. Walsh T.J., Finberg R.W., Arndt C., and National Institute of Allergy and Infectious Diseases Mycoses Study Group. Liposomal amphoterecin for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 340 (1999) 764-771
27. Johnson G.L., Limon L., Trikha G., et al. Acute renal failure and neurotoxicity following oral acyclovir. Ann Pharmacother 28 (1994) 460-463
28. Deray G., Martinez F., and Katlama C. Foscarnet nephrotoxicity. Am J Nephrol 9 (1989) 316
29. Morales J.M., Munoz M.A., and Fernandez Z.G. Reversible acute renal failure caused by combined use of Foscarnet and cyclosporine. Nephrol Dial Transplant 10 (1995) 882
30. Jacobson M.A. Review of toxicities of Foscarnet. J Acquir Immune Defic Syndr 15 (1992) 523
31. Perazella M.A., and Mahnensmith R.L. Trimethoprim-sulfamethoxazole. Hyperkalemia is an important complication regardless of dose. Clin Nephrol 46 (1996) 187-192
32. Greenberg S., Reiser I.W., Chou S.Y., et al. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. Ann Intern Med 119 (1993) 291-295
33. Berg K.J., Gjellestad A., Nordby G., et al. Renal effects of trimethoprim in cyclosporine and azathioprine treated allografts. Nephron 53 (1989) 218-222
34. Alappan R., Perazella M.A., and Buller G.K. Hyperkalemia in hospitalized patients treated with Trimethoprim-sulfamethoxazole. Ann Intern Med 124 (1996) 316-320